Drug Trial Radar · NCT00146757
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old
Last checked: Nov 20, 2026Latest source record: Apr 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Oct 2002
Primary completion
May 2005
Study completion May 2005
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- BioMarin/Genzyme LLC
- First posted
- Sep 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of this study are to evaluate the safety and pharmacokinetics (PK) of enzyme replacement therapy with recombinant human alpha-L-iduronidase \[Aldurazyme® (laronidase)\] in mucopolysaccharidosis I (MPS I) patients less than 5 years old. Efficacy measurements will also be evaluated in this study.
Conditions
- Mucopolysaccharidosis I
- Hurler Syndrome
- Hurler-Scheie Syndrome
- Scheie Syndrome
Interventions
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
100 U/kg every week
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)Biological
200 U/kg every week (Week 26 onwards)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationTime frame: 52 weeks
- Pharmacokinetics - Area Under the (Plasma Concentration-time) Curve (AUC∞)Time frame: 52 weeks
- Pharmacokinetics - Elimination Half Life (t1/2)Time frame: 52 weeks
- Pharmacokinetics - Total Plasma Clearance (CL)Time frame: 52 weeks
- Pharmacokinetics - Volume of Distribution (Vz)Time frame: 52 weeks
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Hôpital E. Herriot
Lyon, France
Johannes Gutenberg Universität
Kinderklinik, Mainz, Germany
Sophia Children's Hospital
Rotterdam, Netherlands
Willink Biochemical Genetics Unit Royal Hospital for Children
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.